Prelude Therapeutics Incorporated CFO Acquires 22,750.00 in Stock - MarketBeat
PRLD Stock | USD 1.30 0.41 46.07% |
About 66 percent of all Prelude Therapeutics' shareholders are curious in acquiring. The analysis of the overall investor sentiment regarding Prelude Therapeutics suggests that quite a large number of traders are confidant. The current market sentiment, together with Prelude Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prelude Therapeutics stock news signals to limit their universe of possible portfolio assets.
Prelude |
Prelude Therapeutics Incorporated CFO Acquires 22,750.00 in Stock MarketBeat
Read at news.google.com
Prelude Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Prelude Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Prelude Therapeutics Fundamental Analysis
We analyze Prelude Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prelude Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prelude Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
Prelude Therapeutics is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
Prelude Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prelude Therapeutics stock to make a market-neutral strategy. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with similar companies.
Peers
Prelude Therapeutics Related Equities
STTK | Shattuck Labs | 10.58 | ||||
GLUE | Monte Rosa | 6.45 | ||||
MLYS | Mineralys Therapeutics, | 4.31 | ||||
KYMR | Kymera Therapeutics | 3.88 | ||||
RZLT | Rezolute | 3.78 | ||||
FHTX | Foghorn Therapeutics | 3.21 | ||||
PHVS | Pharvaris | 2.95 | ||||
CCCC | C4 Therapeutics | 2.60 | ||||
RVMD | Revolution Medicines | 1.78 | ||||
PASG | Passage Bio | 1.54 | ||||
BDTX | Black Diamond | 1.37 | ||||
ANTX | AN2 Therapeutics | 0.79 | ||||
NRIX | Nurix Therapeutics | 1.05 | ||||
MOLN | Molecular Partners | 2.68 | ||||
PEPG | PepGen | 11.25 |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |